Niagen Bioscience, Inc. (NAGE) Financial Statements
Niagen Bioscience, Inc. (NAGE) reported trailing twelve-month revenue of $129.1M (up 11.0% year on year) and net income of $16.0M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $5.7M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NAGENiagen Bioscience, Inc.Follow NAGE — free
—
Price chart with a free account
- Market cap
- 192.3M
- P/E TTM
- 13.5
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.6 | 46.3 | 59.3 | 67.4 | 72.1 | 83.6 | 99.6 | 129.4 | 129.1 | |
| Gross profit | 16.1 | 25.8 | 35.3 | 41.5 | 42.8 | 50.8 | 61.6 | 83.2 | 82.9 | |
| Research & development | 5.5 | 4.4 | 3.4 | 3.8 | 4.8 | 5.0 | 6.0 | 6.3 | 6.5 | |
| Operating income | -33.2 | -31.3 | -19.9 | -27.1 | -18.6 | -5.6 | 7.7 | 16.3 | 10.6 | |
| Pre-tax income | — | — | — | — | — | -4.9 | 8.9 | 18.2 | 17.0 | |
| Income tax | — | — | — | — | — | 0.0 | 0.3 | 0.8 | 1.0 | |
| Net income | -33.3 | -32.1 | -19.9 | -27.1 | -16.5 | -4.9 | 8.6 | 17.4 | 16.0 | |
| Diluted EPS ($) | -0.61 | -0.56 | -0.33 | -0.40 | -0.24 | -0.07 | 0.11 | 0.20 | 0.18 | |
| Diluted shares (mn) | — | — | 61.1 | 67.2 | 69.7 | 75.0 | 78.1 | 85.4 | — |
USD millions · SEC XBRL
Niagen Bioscience, Inc. — questions
- What is Niagen Bioscience, Inc.'s revenue?
- $129.1M over the twelve months to 2026-06-30, up 11.0% year on year, from its 10-Q and 10-K filings.
- What is Niagen Bioscience, Inc.'s net income?
- $16.0M over the twelve months to 2026-06-30.
- What is Niagen Bioscience, Inc.'s free cash flow?
- $5.7M over the twelve months to 2026-06-30.
- What are Niagen Bioscience, Inc.'s diluted earnings per share?
- $0.18 over the twelve months to 2026-06-30.
Every figure on this page comes from Niagen Bioscience, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.